-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Initiates Coverage On MBX Biosciences with Overweight Rating, Announces Price Target of $66

Benzinga·01/28/2026 14:45:03
Listen to the news
Barclays analyst Eliana Merle initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Overweight rating and announces Price Target of $66.